Atenolol Tablets
Function and Efficacy
It is a selective beta-1 adrenergic receptor blocker with no membrane stabilizing effect and endogenous sympathomimetic activity. However, it does not inhibit the bronchodilator effect of isoproterenol. Its mechanism of lowering blood pressure and reducing myocardial oxygen consumption is the same as that of propranolol. Large-scale clinical trials have confirmed that atenolol can reduce the mortality rate of acute myocardial infarction within 0 to 7 days. The therapeutic dose has no significant inhibition on myocardial contractility.
Ingredients
Chemical name: 4-[3-[(1-methylethyl)amino-2-hydroxy]propoxy]phenylacetamide, molecular formula: C14H22N2O3, molecular weight: 266.34
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| AtenololIngredients |
A selective β1-adrenergic receptor blocker with no membrane stabilizing effect and endogenous sympathomimetic activity. However, it does not inhibit the bronchodilator effect of isoproterenol. Its mechanism of lowering blood pressure and reducing myocardial oxygen consumption is the same as that of propranolol. Large-scale clinical trials have confirmed that atenolol can reduce the mortality rate of acute myocardial infarction within 0 to 7 days. The therapeutic dose has no significant inhibition on myocardial contractility. More |
29122-68-7 | 48 | |
| AtenololIngredients |
It is a selective beta-1 adrenergic receptor blocker with no membrane stabilizing effect and endogenous sympathomimetic activity. However, it does not inhibit the bronchodilator effect of isoproterenol. Its mechanism of lowering blood pressure and reducing myocardial oxygen consumption is the same as that of propranolol. Large-scale clinical trials have confirmed that atenolol can reduce the mortality rate of acute myocardial infarction within 0 to 7 days. The therapeutic dose has no significant inhibition on myocardial contractility. More |
29122-68-7 | 48 |
Appearance
This product is a white tablet or sugar-coated tablet, which appears white after removing the sugar coating.
Indication
It is mainly used to treat hypertension, angina pectoris, and myocardial infarction, and can also be used for arrhythmia, hyperthyroidism, and pheochromocytoma.
Usage and Dosage
Common oral adult dose: 6.25~12.5mg each time, twice a day, gradually increase to 50~200mg as needed and tolerated. In case of renal impairment, if creatinine clearance is less than 15ml/(min.1.73m2), 25mg per day; if 15~35ml/(min.1.73m2), up to 50mg per day.
Adverse Reactions
In patients with myocardial infarction, the most common adverse reactions are hypotension and bradycardia; other reactions may include dizziness, cold limbs, fatigue, weakness, gastrointestinal discomfort, depression, hair loss, thrombocytopenia, psoriasis-like skin reactions, psoriasis exacerbation, rash and dry eyes, etc. Rarely, it may cause heart block in sensitive patients.
Precautions
1. II-III degree heart block. 2. Cardiogenic shock. 3. Sick sinus syndrome and severe sinus bradycardia.
Drug Interactions
When used in combination with other antihypertensive drugs and diuretics, their antihypertensive effect can be enhanced. Be especially cautious when using Class I antiarrhythmic drugs, verapamil, and anesthetics. Beta-blockers can aggravate the rebound of hypertension caused by discontinuation of clonidine. If the two drugs are used in combination, this drug should be discontinued a few days before discontinuation of clonidine. If this drug is used to replace clonidine, the course of beta-blocker treatment should be started a few days after stopping taking clonidine.
Storage
Keep sealed.
Packaging Specification
6.25mg
Manufacturer
China Resources SAIKE Pharmaceutical Co., Ltd.
-
Founded in:
1981-03-23 -
Address:
Room 2111, 21F, Building 402, Baiziwanxili, Chaoyang District, Beijing -
Tax NO.:
91110000101208804Q -
Registered Funds:
168.55 million yuan -
Email: